Bibliografía del artículo
1. Rubio G, Casas M. Revisión del tratamiento de la esquizofrenia en individuos con abuso de drogas. Actas Españolas de Psiquiatría 29:124-130, 2001.
2. Mueser K, Yarnold PR, Levinson DF. Prevalence of substance abuse in schizophrenia: Demographic and clinical correlates. Schizophr Bull 16:31-56, 1990.
3. Regier DA, Farmer ME, Rae DS. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area Study. JAMA 264:2511-2518, 1990.
4. Rubio G. Métodos diagnósticos de trastornos psiquiátricos en poblaciones con abuso de drogas. En: J. Cabrera (Eds). Patología Dual. Madrid. Agencia Antidroga. Madrid, pp. 18-31, 1998.
5. Green AI, Zimmer SV, Strous RD, Schilkraut JJ. Clozapine for comorbid substance use disorder and schizophrenia: Do patients with schizophrania have a reward-deficiency syndrome that can be ameliorated by clozapine. Harv Rev Psychiatry 6:287-296, 1999.
6. Weiss RD. Adherence to pharmacotherapy in patients with alcohol and opioid dependence. Addiction 99:1382-1392, 2004.
7. Ley A, Jeffery DP, McLaren S, Siegfried N.Treatment programmes for people with bothsevere mental illness and substance misuse (Cochrane Review); in The Cochrane Library,Issue 2. Oxford, Update Software, 2002.
8. San L, Arranz B, Martínez-Raga J. Antipsichotic Drug Treatment of schizophrenic patients with substance abuse disorders. Eur Addict Res 13:230-43, 2007.
9. Ziedonis DM, D'Avanzo K. Schizophrenia and substance abuse. En: Kranzler HR, Rounsaville B (eds). Dial Diagnosis and Treatment. New York, Marcel Dekker Inc. pp. 427-466, 1998.
10. Rubio G, Martínez I, Ponce G, López-Muñoz F, Alamo C, Jiménez-Arriero MA, Palomo T. Risperidone versus zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity: a long-term randomized, controlled, single-blind crossover study. J Eur Psychiat 20:133-146, 2006.
11. Rubio G, Martínez I, Ponce G, Jiménez-Arriero MA, López-Muñoz, Alamo C. Long-acting injectable risperidone versus zuclopenthixol in the treatment of schizophrenia with substance abuse. The Canadian Journal of Psychiatry 51:531-539.
12. Rubio G, Martínez-Gras, Ponce G, Jiménez-Arriero MA, López-Muñoz F, Alamo C, Calcedo A. Long-acting injectable risperidone versus zuclopenthixol in the treatment of schizophrenia with substance abuse. Eur Psychiatr 21(Suppl 1):117S,.
13. Rubio G, Martínez I, Ponce G, López-Muñoz F, Alamo C, Jiménez-Arriero MA, Palomo T. Risperidone versus zuclopenthixol in the treatment of schizoprenia with substance abuse comorbidity: a long-term controlled study. European Neuropsychopharmacology (Supp 3):S476, 2005.
14. Hoyberg OJ, Fensbo C, Remvig J. Rsiperidone versus perphenazine in the treatment of chronic schizophrenic in-patients with acute exacerbations. Acta Psychiat Scand 88:395-402, 1993.
15. Marder R, Meibach R. Rsperidone in the treatment of schizophrenia. Am J Psychiatry 151:825-835, 1994.
16. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the fivedimensions of schizophrenia derived by factors analysis: combined results of theNorth American Trial. J Clin Psychiatry 58:538-46, 1997.
17. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel group study versus haloperidol. Br J Psychiatry 166:712-26, 1995.
18. Schotte A, Janssen PFM, Gommeren W, Luyten WHML, Van Gompel P, Lesage AS. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124:57-73, 1996.
19. Yoshimura R, Nakamura J, Ueda N, Terao T. Effect of risperidone on plasma free 3-methoxy-4-hydroxyphenylglycol (pMHPG) levels in schizophrenic patients: relationship among plasma concentrations of risperidone and 9-hydroxyrisperidone, pMHPG levels, and clinical improvement. Int Clin Psychopharmacol 15:175-80, 2000.
20. Möller HJ, Müller H, Borison RL, Schooler NR, Chouinard G. A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. Eur Arch Psychiatr Clin Neurosci 245:45-49, 1995.
21. Möller HJ, Müller H. Statistical differentiation between direct and indirect effects of neuroleptics on negative symptoms. Eur Arch Psychiatr Clin Neurosci 247:1-5, 1997.
22. Smelson DA, Losonczy MF, Davis CW, Kaune M, Williams J, Ziedonis D. Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. Can J Psychiatry 47:671-675, 2002.
23. Casas M, Gutiérrez M, Gibert J, Bobes J, Roncero C, Octavio I. Risperidona en el tratamiento de pacientes psicóticos con abuso y dependencia de opiáceos. Actas Esp Psiquiatr 29:380-385, 2001.
24. Buckley P, Thompson PA, Way L, Meltzer HY. Substance abuse among patients with treatment-resistant schizophrenia: Characteristics and implications for clozapine. Am J Psychiatry 151:385-389, 1994.
25. Conley R, Gale E, Hirsch K. Olanzapine response in therapy-refractory schizophrenia with substance abuse. Schizophr Res 33:95-101, 1998.
26. Buckley P, Thompson PA, Way L, Meltzer HY. Substance abuse among patients with treatment-resistant schizophrenia: Characteristics and implications for clozapine. Am J Psychiatry 151:385-389, 1994.
27. McEvoy J, Freudenreich O, McGree M. Clozapine decreases smoking in patients with chronic schizophrenia. Biol Psychiatry 37:550-552, 1995.
28. Brunette LM, Mueser KT, Xie H, Drake RE. Relationships between symptoms of schizophrenia and substance abuse. J Nerv Ment Dis 185:13-20, 1997.
29. Zimmet SV, Strous RD, Burgess ES, Kohnstamm S, Green AL. Effects of clozapine on substance use in patients with schizophrenia and psychoaffective disorders: A retrospective survey. J Clin Psychopharmacol 20:94-98, 2000.
30. Drake RE, Xie H, McHugo GJ, Green AI. The effects of clozapine on alcohol and drug use disorders among schizophrenic patients. Schizophr Bull 26:441-449, 2000.
31. Marchi M, Raiteri M. Nicotine autoreceptors mediating enhancement of acetylcholine release become operative in conditions of impaired cholinergic presynaptic function. J Neurochem 67:1974-1981, 1996.
32. Rubio G, Jiménez-Arriero MA, Manzanares J, Ponce G, Palomo T. Tratamiento farmacológico de la esquizofrenia en pacientes con abuso/dependencia de drogas. En: Rubio G, Hernández JA, Jiménez-Arriero MA, Palomo T (Eds). Guía para el tratamiento de los pacientes con esquizofrenia. Madrid, Fundación Cerebro y Mente pp. 219-244, 2002.
33. See RE, Aravagiri M, Ellison GD. Chronic neuroleptic treatment in rats produces persisting changes in GABA-A and dopamine D-2, but not dopamine D-1, receptors. Life Sci 44:229-236, 1989.
34. Grace AA. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41:1-24, 1991.
35. Schotte A, Janssen PFM, Gommeren W, Luyten WHML, Van Gompel P, Lesage AS, De Loore K, Leysen JE. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124:57-73, 1996.
36. Durell J, Lechtenberg B, Corse S, Frances R. Intensive case management of persons with chronic mental illness who abuse substances. Hosp Comm Psychiatr 44:415-416, 1993.
37. Jerrell JM, Ridgley MS. Comparative effectiveness of three approaches to serving people with severe mental illness and substance use disorders. J Nerv Ment Dis 183:566-576, 1995.
38. Mueser KT, Valentier DP, Agresta J. Coping with negative symptoms of schizophrenia: Patient and familiy perspectives. Schizophr Bull 23:329-339, 1997.
39. Fridell M. Psychosocial Treatment for Drug Dependence. In: Treating Alcohol and Drug Abuse. Beglund M, Thelander S, Jonsson E (Eds). Weinheim, Wiley-VC, 325-413, 2003.
40. Huttunen MO, Piepponen T, Rantanen H, Larmo I, Nyholm R, Raitasuo V. Risperidone versus Zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial. Acta Psychiatr Scand 91:271-277, 1995.